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OBJECTIVE—Non–Fc-binding anti-CD3–speciﬁc antibodies
represent a promising therapy for preserving C-peptide produc-
tion in subjects with recent-onset type 1 diabetes. However, the
mechanisms by which anti-CD3 exerts its beneﬁcial effect are
still poorly understood, and it is questionable whether this
therapeutic approach will prove durable with regard to its ability
to impart metabolic preservation without additional actions
designed to maintain immunological tolerance. We used the NOD
mouse model to test whether rapamycin, a compound well-
known for its immunomodulatory activity in mice and humans,
could increase the therapeutic effectiveness of anti-CD3 treat-
ment in type 1 diabetes.
RESEARCH DESIGN AND METHODS—Rapamycin was ad-
ministered to diabetic NOD mice simultaneously with anti-CD3
or to NOD mice cured by anti-CD3 therapy. The ability of this
combined therapy to revert type 1 diabetes and maintain a state
of long-term tolerance was monitored and compared with that of
anti-CD3 therapy alone.
RESULTS—Rapamycin inhibited the ability of anti-CD3 to re-
vert disease without affecting the frequency/phenotype of T-cells.
Rapamycin also reinstated diabetes in mice whose disease was
previously reversed by anti-CD3. Withdrawal of rapamycin in
these latter animals promptly restored a normoglycemic state.
CONCLUSIONS—Our ﬁndings indicate that, when combined
with anti-CD3, rapamycin exerts a detrimental effect on the
disease outcome in NOD mice for as long as it is administered.
These results suggest strong caution with regard to combining
these treatments in type 1 diabetic patients. Diabetes 58:
875–881, 2009
T
he NOD mouse is widely used as a model of
human type 1 diabetes (1). Whereas a large
number of therapeutic approaches have shown
success in preventing type 1 diabetes in NOD
mice, agents demonstrating the clear ability to reverse
established disease and restore self-tolerance in this ani-
mal model have been far more difﬁcult to identify (2).
Among the limited number of treatments demonstrated to
revert established disease in diabetic NOD mice is the
non–Fc-binding anti-CD3ε antibody (anti-CD3) (3). Indeed,
a short-term treatment with anti-CD3 at the time of diabe-
tes onset is sufﬁcient to reverse the disease, induce
long-term remission, and prevent recurrent immune re-
sponses, including those against transplanted syngeneic
pancreatic islets (4). The exact mechanism of action by
which anti-CD3 provides this beneﬁcial effect is still not
fully known, but it is clear that its tolerogenic capacity
develops in two consecutive phases. The ﬁrst phase,
known as the induction phase, occurs concomitantly with
antibody administration via three distinct nonmutually
exclusive mechanisms: 1) antigenic downmodulation of
the T-cell receptor–CD3 complex, 2) induction of apopto-
sis that preferentially affects activated T-cells, and 3)
induction of anergy in T-cells (5). The second phase,
known as maintenance phase, is long-term in its mode of
action and involves the generation of inducible TGF-–
dependent CD4
 regulatory T-cells (Tregs) that coexist
with pathogenic T-cells (6). Tregs are a specialized T-cell
subset essential for maintaining peripheral tolerance and
preventing autoimmune disease (7). CD4
 Tregs are often
categorized into two major subgroups based on their
ontogeny. The ﬁrst, naturally occurring CD4
CD25

FOXP3
 Tregs (nTregs), originate from the thymus. The
second, so-called inducible Tregs (iTregs), are generated
in the periphery. Each of these Treg subsets has been
shown to be required for tolerance induction to self- and
nonself-antigens (7).
Given the therapeutic effectiveness of anti-CD3 in re-
versing type 1 diabetes in NOD mice, the clinical efﬁcacy
of this drug was tested in two independent clinical trials
conducted in new-onset type 1 diabetic patients. Anti-CD3
treatment was shown to be effective in preventing loss of
insulin production for at least 1 year following diagnosis,
but its long-term efﬁcacy was only evident in a limited
group of patients (8,9). Given this ﬁnding, it was hypoth-
esized that the effectiveness of anti-CD3 therapy might be
improved by its use in combination with other tolerogenic
treatments (10).
We previously demonstrated that rapamycin, a non–
calcineurin-based inhibitor used to prevent acute graft
rejection following allogeneic transplantation (11), allows
for in vitro expansion of murine (12) and human (13)
CD4
CD25
FOXP3
 nTregs. Rapamycin also expands
CD4
CD25
FOXP3
 nTregs in vivo in pre-diabetic NOD
mice and has a synergistic effect with interleukin (IL)-10
in blocking disease development and restoring self-
tolerance (14). In addition, rapamycin monotherapy in
patients with long-lasting type 1 diabetes patients im-
proves CD4
CD25
FOXP3
 nTreg function (15). These
data provide strong evidence that rapamycin is, in fact,
a protolerogenic compound that could be used to boost
From the
1San Raffaele Diabetes Research Institute, Milan, Italy;
2San Raffaele
Telethon Institute for Gene Therapy, Milan, Italy; the
3Department of
Pathology, University of Florida, Gainesville, Florida; and the
4Universita `
Vita-Salute San Raffaele, Milan Italy.
Corresponding authors: Maria-Grazia Roncarolo, m.roncarolo@hsr.it, and
Manuela Battaglia, manuela.battaglia@hsr.it.
Received 16 October 2008 and accepted 5 January 2009.
Published ahead of print at http://diabetes.diabetesjournals.org on 16 January
2009. DOI: 10.2337/db08-1432.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
BRIEF REPORT
DIABETES, VOL. 58, APRIL 2009 875the tolerogenic activity previously ascribed to anti-CD3
treatment in vivo. Therefore, we tested whether rapa-
mycin could be combined with anti-CD3 therapy in
curing type 1 diabetes and reinforcing the long-term
tolerance in NOD mice. Surprisingly, we observed that
rapamycin therapy not only blocks the ability of anti-
CD3 treatment to cure type 1 diabetes in NOD mice but
also reverts its curative effect once established. These
previously unreported and unexpected results raise
serious questions regarding the effectiveness of combin-
ing rapamycin and anti-CD3 therapy to induce tolerance
in type 1 diabetes patients.
RESEARCH DESIGN AND METHODS
Animals. NOD/LtJ female mice were purchased from Charles River (Calco,
Italy). All mice were maintained under speciﬁc pathogen-free conditions.
Animal care procedures were performed according to protocols approved by
the Hospital San Raffaele Institutional Animal Care and Use Committee
(IACUC no. 350).
Blood glucose monitoring. Blood glucose was measured in the morning
three times a week using a Glucometer Ascensia Breeze 2 Glucose Meter
(Bayer, Leverkusen, Germany). A diagnosis of diabetes was made after a
glucose measurement of 300 mg/dl to ensure no spontaneous disease
reversal. A relapse of disease in treated animals was considered following two
consecutive glucose measurements of 200 mg/dl, levels at which spontane-
ous diabetes reversal never occurred in any of the tested mice (data not
shown).
Treatment. After diabetes onset, female NOD mice (aged 22  7 weeks) were
treated with varying doses of the non–Fc-binding anti-CD3ε F(ab)2 clone
145-2C11 (Bio Express, West Lebanon, NH) or mAb isotype control (Golden
Syrian Hamster IgG; eBioscience, San Diego, CA), according to the glycemia
levels, the same day they were found to have diabetes. Rapamycin (Rapam-
une; Wyeth Europe, Taplow, U.K.) was diluted in water and administered by
gavage once a day at 1 mg/kg, a dose that we and others previously
demonstrated not to be toxic to pancreatic islets (14,16). Recombinant human
IL-10 (BD Biosciences, Mountain View, CA) was diluted in PBS and adminis-
tered twice a day at a dose of 0.05 mg/kg i.p. (14).
Intraperitoneal glucose tolerance test. Mice were fasted 16 h before
receiving 2 g/kg glucose i.p. (30% glucose solution). Glucose tolerance was
monitored via tail-vein sampling at time 0 (just before glucose solution
injection) and 5, 10, 15, 20, 25, 30, 45, 60, 75, 90, and 120 min after glucose
solution injection. All statistical analyses were performed using a two-tailed
Student’s t test. A P value of 0.05 was deemed signiﬁcant.
RESULTS
To deﬁne a suboptimal dose of anti-CD3 amenable to
combinational therapy studies (i.e., having a second agent
that improves the action of the ﬁrst) and to identify the
inﬂuence of starting glycemia on the ability to reverse
disease, we ﬁrst grouped NOD mice based on degree of
hyperglycemia and treated with various dosages of anti-
CD3 (Fig. 1A). Using this strategy, several suboptimal
anti-CD3 dosages leading to a wide range of diabetes
reversal rates (i.e., from 35 to 75%) were identiﬁed. The
efﬁcacy of the anti-CD3 treatment was strictly dependent
on the dosage, as previously shown (17,18), but was also
inﬂuenced by glucose levels at time of treatment. Figure
1B shows the glucose levels of each of the animals treated
with the best effective anti-CD3 dosage (i.e., 50 g  3
doses in mice with 300–349 mg/dl glycemia levels), dem-
onstrating a rapid and uniform diabetes reversal in six of
eight animals treated (Fig. 1B).
Although rapamycin has a strong immunomodulatory
capacity in pre-diabetic NOD mice (14,16), rapamycin
monotherapy did not lead to disease reversal in any of the
diabetic mice (Fig. 1C). To test whether rapamycin coop-
erates with anti-CD3 to reverse diabetes and reinforce the
development of long-term tolerance, diabetic NOD mice
were treated with rapamycin and the anti-CD3 dosage that
showed the weaker ability to reverse disease (i.e., 35%
diabetes reversal). The concomitant administration of
rapamycin and anti-CD3 did not lead to enhanced diabetes
reversal in any of the animals tested (Fig. 2A); rather, the
inclusion of rapamycin blocked the ability of anti-CD3 to
impart its beneﬁcial effect. The deleterious inﬂuence of
rapamycin on the anti-CD3 reversal capacity was even
observed when rapamycin was coadministered with dos-
FIG. 1. Anti-CD3 and rapamycin monotherapy in diabetic NOD mice.
Female diabetic NOD mice were grouped based on glycemia levels
(300–349 [gray bar] and 350–400 mg/dl [white bar]) and treated with
various anti-CD3 dosages. Percentages of diabetes reversal and num-
ber of mice in each group are shown (A). Glucose levels of the eight
NOD mice with 300–349 mg/dl glycemia and treated with three 50-g
doses of anti-CD3 (75% diabetes reversal) are shown (B). Female
diabetic NOD mice with 300–400 mg/dl glycemia were treated with
rapamycin alone (1 mg/kg daily during the entire time of observation
[]) or anti-CD3 alone (50 g  3 doses at days 0, 1, and 2 []).
Percentage of diabetes reversal and number of mice are shown (C).
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(Fig. 2B). Of 10 diabetic NOD mice, 9 remained diabetic
when treated with rapamycin and anti-CD3 at the highest
effective dose (i.e., 70% diabetes reversal) (Fig. 2C).
To evaluate whether other pro-tolerogenic compounds
acted similarly to rapamycin when combined with anti-
CD3, we tested IL-10, an immunomodulatory cytokine with
known tolerogenic potential in vivo (14,19). When coad-
ministered with anti-CD3 in diabetic NOD mice, the addi-
tion of IL-10 did not interfere with the anti-CD3
therapeutic activity (Fig. 2D). These data demonstrate that
the tolerogenic capacity of anti-CD3 during the ﬁrst induc-
tion phase is completely halted by rapamycin, but not by
IL-10 therapy, in diabetic NOD mice.
To deﬁne whether the detrimental effect of rapamycin
on anti-CD3 therapy was related to changes in the T-cell
compartment, we tested the percentages of circulating
CD4
 and CD8
 T-cells and the frequency of CD4
CD25

FoxP3
 T-cells in the pancreatic lymph nodes of NOD
mice treated with anti-CD3 alone or in combination with
rapamycin. Circulating CD4
 T-cells were depleted upon
anti-CD3 treatment irrespective of the presence of rapa-
mycin, whereas CD8
 T-cells were only partially affected
(Fig. 3A). Similarly, rapamycin did not alter the frequency
of CD4
CD25
FoxP3
 T-cells in the pancreatic lymph
nodes 2 weeks after anti-CD3 treatment (Fig. 3B–C).
Contrary to what was previously demonstrated (6), anti-
CD3–treated NOD mice did not show a selective increase
of CD4
CD25
 T-cells in the pancreatic lymph nodes
compared with control NOD mice. This might be due to
the reduced anti-CD3 dosage used in our study (i.e., 50
g  3 doses) compared with that used by Belghith et al.
(i.e., 50 g  5 doses) (6), which might lead to different
kinetics in the expansion of CD4
CD25
 T-cells.
The anti-CD3 maintenance phase in NOD mice is a
stable condition of tolerance that is no longer dependent
on the presence of the antibody. Given our previous
results, we tested whether rapamycin negatively affects
this stable condition of reversed type 1 diabetes. Five
weeks after anti-CD3–mediated diabetes reversal, normo-
glycemic NOD mice were treated with rapamycin. Quite
remarkably, all previously cured mice returned to a state
of hyperglycemia within 7 weeks of rapamycin adminis-
tration, whereas rapamycin-untreated animals showed no
signs of diabetes recurrence (Fig. 4A). To further delay the
interval between anti-CD3 intervention and rapamycin
administration, normoglycemic NOD mice were treated
with rapamycin 30 weeks after anti-CD3–mediated diabe-
tes reversal. Consistent with the aforementioned observa-
tions, two of three anti-CD3–cured NOD mice returned to
a diabetic state within 10 weeks of rapamycin administra-
tion, whereas all rapamycin-untreated animals remained
normoglycemic (Fig. 4B). This phenomenon was revers-
ible and strictly dependent on the presence of rapamycin,
as all mice treated for 230 days with rapamycin promptly
returned to a normoglycemic state upon drug removal.
To evaluate the metabolic parameters underlying this
ﬁnding, a glucose tolerance test was performed in NOD
mice previously treated with anti-CD3 and under rapamy-
cin treatment. Although two of three rapamycin-treated FIG. 2. Simultaneous administration of anti-CD3 and rapamycin or
IL-10 in diabetic NOD mice. Female diabetic NOD mice were treated
with anti-CD3 alone or in conjunction with rapamycin (1 mg/kg) or
IL-10 (0.05 mg/kg) during the entire time of observation. NOD mice
were treated with various doses of anti-CD3. Mice with 350–400 mg/dl
glycemia were treated with 25 g anti-CD3 (one dose) alone ()o ri n
conjunction with rapamycin ()( A). Mice with 300–349 mg/dl glyce-
mia were treated with 18 g anti-CD3 (one dose) alone ()o ri n
conjunction with rapamycin ()( B). Mice with 300–400 mg/dl glyce-
mia were treated with 50 g anti-CD3 (three doses) alone ()o ri n
conjunction with rapamycin ()( C). Mice with 300–400 mg/dl glyce-
mia were treated with 50 g anti-CD3 (three doses) alone ()o ri n
conjunction with IL-10 ()( D). Percentages of diabetes reversal and
number of mice are shown.
A. VALLE AND ASSOCIATES
DIABETES, VOL. 58, APRIL 2009 877mice were hyperglycemic at the time of analysis (as shown
in Fig. 4B), all three demonstrated a glucose response
similar to that observed in diabetic untreated NOD mice,
while control anti-CD3–cured NOD mice showed a glu-
cose response superimposable to that of normoglycemic
untreated animals (Fig. 4C–D). These data proved the
inability of active rapamycin treatment to control glucose
homeostasis. Overall, rapamycin reverts the stable toler-
ance condition established in anti-CD3–cured NOD mice
while it is administered.
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FIG. 3. T-cell frequency and phenotype in NOD mice treated with anti-CD3 or anti-CD3 and rapamycin. Diabetic NOD mice were treated with
anti-CD3 alone (50 g  3 doses, n  6, [f]) or in combination with rapamycin (1 mg/kg per day, n  5, [ ]). Peripheral blood was collected at
different time points after treatment, and circulating CD4
 (left) and CD8
 (right) T-cells were analyzed by a ﬂuorescence-activated cell sorter.
Percentages of CD4
 and CD8
 T-cells within the CD45
 cells are shown. (F), mean  SD of peripheral CD4
 and CD8
 T-cells in nondiabetic
NOD mice within CD45
 cells (n  10) (A). Pancreatic lymph nodes from normoglycemic untreated (n  4), diabetic untreated (n  5),
anti-CD3–treated (50 g  3 doses) (n  2), and anti-CD3– (50 g  3 doses) plus rapamycin treated (n  5) NOD mice were analyzed by a
ﬂuorescence-activated cell sorter 3 weeks after treatment. One representative plot for each group, after CD4
 T-cell gating, is shown. The big
gate includes all CD25
 T-cells, whereas the small gate includes only CD25
FoxP3
 T-cells. Numbers indicate the relative percentages in each
gate (B). Percentages of means  SD of CD25
 T-cells (left panel) and CD25
FoxP3
 T-cells (right panel) within CD4
 T-cells in the pancreatic
lymph nodes are shown (C).
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With prior data demonstrating that rapamycin is a pro-
tolerogenic compound both in vitro and in vivo (12,13,15)
as well as information from the ﬁrst clinical trials with
anti-CD3 in recent-onset type 1 diabetic patients suggest-
ing that this form of therapy can be improved (8,9), we
tested the speciﬁc hypothesis that rapamycin would aug-
ment the therapeutic effectiveness of anti-CD3–mediated
type 1 diabetes reversal in NOD mice. Against all expec-
tations, we observed that rapamycin not only blocks the
ability of anti-CD3 treatment to cure overt hyperglycemia
in NOD mice but also breaks its curative effect while it is
administered.
Previous data demonstrate that cyclosporine A (20),
anti–TGF-, and anti–CTLA-4 neutralizing antibodies (6)
block the reversal capacity of anti-CD3 in the induction
phase while cyclophosphamide breaks anti-CD3–mediated
tolerance during the maintenance phase (20). The mecha-
nisms by which these compounds counteract the anti-CD3
effect have been elucidated. Cyclosporine A blocks T-cell
activation and T-cell depletion mediated by activation-
induced cell death, and anti–TGF- and anti–CTLA-4
monoclonal antibodies impede the generation and/or func-
tion of inducible TGF-–dependent Tregs, whereas cyclo-
phosphamide depletes Tregs. Rapamycin inhibits both
phases of anti-CD3–induced tolerance. In addition, rapa-
mycin allows T-cell activation and activation-induced cell
death (11), permits generation of inducible Tregs (21–23),
and does not selectively deplete Tregs (12,24,25). In fact,
T-cell frequency and phenotype in anti-CD3–rapamycin–
treated mice were identical to those of anti-CD3–treated
NOD mice. It is therefore unlikely that rapamycin alters
the anti-CD3 activity through the same inhibitory mecha-
nisms demonstrated for the abovementioned compounds.
It has been recently proposed that the reduced IL-2
production by T effector cells in NOD mice is the root
cause of the progressive loss of Treg–T effector cell
balance in the islets, leading to -cell destruction (26).
Anti-CD3 therapy might restore IL-2 production, leading to
stable disease reversal. Rapamycin, by inhibiting signal
transduction delivered by IL-2, might directly interfere
with this pathway, nowadays considered so crucial for
maintaining immunological tolerance in NOD mice. Exper-
iments are currently ongoing to test this hypothesis.
Alternative mechanisms that can explain the unique
effect of rapamycin in anti-CD3–treated NOD mice may be
related to -islet physiology. It has recently been demon-
strated that rapamycin induces fulminant diabetes in the
Psammomys obesus mouse model of nutrition-dependent
type 2 diabetes by increasing insulin resistance and reduc-
ing -cell function and mass through increased apoptosis
(27). The fundamental function of mammalian target of
rapamycin–signaling in -cells, which is blocked by rapa-
mycin, has been conﬁrmed by others (28,29). Rapamycin
might therefore have a negative effect directly on the islets
rather than blocking the activity of anti-CD3 in NOD mice.
anti-CD3 mAb
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anti-CD3 post-rapa mAb
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FIG. 4. Delayed rapamycin administration in anti-CD3–treated NOD
mice. According to their glycemia levels, 28 female NOD mice were
previously cured with anti-CD3 (). Thirty-ﬁve days after anti-CD3
mAb–mediated diabetes reversal, four mice were treated with rapamy-
cin (f) and 24 were left untreated (). Rapamycin was administered
during the entire time of observation. Percentages of diabetes reversal
and number of mice are shown (A). According to their glycemia levels,
24 female NOD mice were previously cured with anti-CD3 (). One
hundred and eighty days after anti-CD3–mediated diabetes reversal,
three mice were treated with rapamycin () and 21 were left untreated
(). Rapamycin was administered for 230 days and then withdrawn.
Percentages of diabetes reversal and number of mice are shown (B).
Intraperitoneal glucose tolerance test was performed in three normo-
glycemic untreated NOD mice, three diabetic NOD mice, six normogly-
cemic anti-CD3–cured mice, and three mice previously cured with
anti-CD3 but again diabetic upon rapamycin treatment. Intraperito-
neal glucose tolerance test was performed in the latter group during
rapamycin treatment (i.e., 320 days after anti-CD3 mAb treatment).
The average glucose levels per each time point and the best-ﬁtting
curve for each group are shown (C). The area under the curve (AUC)
from time 0 to 120 min after glucose injection for all the animals
included in panel B is shown (D).
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vations by our group (14) and others (16) in pre-diabetic
NOD mice wherein rapamycin monotherapy signiﬁcantly
protected animals from disease development. In addition,
diabetic NOD mice treated with rapamycin did not develop
a more aggressive disease, in terms of glycemia, than
untreated mice (A.V., unpublished data).
An alternative hypothesis is that rapamycin interferes
with -cell proliferation, as demonstrated in speciﬁc ex-
perimental settings such as pregnancy (30) and transgenic
mice (31). However, at this time, there are no data
indicating that anti-CD3 leads to -cell proliferation. In-
deed, currently available data suggest the opposite: recov-
ery of metabolic control following anti-CD3 therapy may
be due to mending of -cells that had been already present
but not functional in the pancreas at the moment of
hyperglycemia rather than -cell proliferation (18,32).
Future experiments will investigate the pancreata of NOD
mice treated with rapamycin, with or without anti-CD3, in
order to further understand the mechanisms underlying its
deleterious action.
Rapamycin monotherapy in long-lasting type 1 diabetic
patients does not aggravate the autoimmune disease but,
rather, improves the suppressive function of nTregs (15).
One should therefore expect that rapamycin behaves
similarly in the case of new-onset type 1 diabetes. How-
ever, the disease in early-onset type 1 diabetic subjects
appears both metabolically and immunologically different
from that observed in long-lasting patients, and rapamycin
might have a different outcome in diverse patient popula-
tions. A clinical trial combining rapamycin and IL-2 re-
cently began with new-onset type 1 diabetic patients
(http://www.clinicaltrials.gov/ct2/show/NCT00525889?term
rapamuneandil-2&rank1). Of note, no preclinical
studies demonstrating the curative potential of rapamy-
cin–IL-2 therapy have been reported. Our data suggest
caution in designing rapamycin-based combinational treat-
ments because the addition of rapamycin to anti-CD3
therapy in early-onset diabetic NOD mice completely
abolished the anti-CD3 therapeutic effect.
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